We describe outcomes after HLA-matched sibling bone marrow transplantation (BMT) for 179 patients with β -thalassemia major. The median age at transplantation was 7 years and the median follow-up was 6 years. The distribution of Pesaro risk class I, II and III categories was 2%, 42%, and 36%, respectively. The day-30 cumulative incidence of neutrophil recovery and day-100 platelet recovery were 90% and 86%, respectively. Seventeen patients had graft failure, which was fatal in 11. Six of 9 patients with graft failure are alive after a second transplant. The day-100 probability of acute graft-versus-host disease (GVHD) and
INTRODUCTION β
-thalassemia major, a genetic defect that causes reduced or absent β -globin synthesis, results in an imbalanced accumulation of α -globin chains and ineffective erythropoiesis with hemolysis 1 . The hallmarks of treatment include regular red blood cell (RBC) transfusions with iron chelation therapy for transfusion-related iron overload and supportive care to treat the complications of iron overload 2, 3 . However, the only curative therapy is replacement of the defective gene by hematopoietic cell transplantation [4] [5] [6] Over the past two decades, transplantation as a therapeutic option for thalassemia has undergone considerable investigation and refinement. The largest experience occurred in Pesaro, Italy where a standard pre-transplantation risk assessment was developed. It divides patients into 3 risk classes based upon liver size by physical exam, the presence or absence of fibrosis by liver biopsy and adherence to regular iron chelation 4-6 . In the initial reports, outcomes after transplantation were affected significantly by the pre-transplant risk status.
More recently, modifications to the conditioning regimen have been employed to reduce the risk of transplantation-related complications in high-risk recipients. As a result, outcomes after transplantation have become more similar across risk categories [7] [8] [9] [10] [11] . The most recent results after HLA-matched sibling bone marrow transplant (BMT) for Pesaro class 1 or 2 and class 3 recipients show thalassemia-free survival probabilities of 87, 85, and 80%, respectively. Despite these improvements, pre-transplant transfusion exposures and organ damage from iron overload still appear to impact transplantation outcomes negatively. In the most recent update, the transplant-related mortality (TRM) in class 1 or 2 and class 3 patients was 3% and 10%, respectively, and 8 -12 % of pediatric recipients experienced graft rejection
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Most patient series outside Italy have observed comparatively worse outcomes after HLA-matched sibling BMT for thalassemia major [12] [13] [14] [15] [16] . While the reasons for this disparity are unknown, there have been differences in recipient ethnicity, in the ability to assign a pretransplantation risk status, in how patients were prepared for transplantation and in graftversus-host disease (GVHD) prophylaxis that might account for the disparate outcomes.
There is also the possibility of a center effect that might have contributed to an apparent poorer outcome in the smaller patient series outside Italy. 
End points
Primary endpoints were acute GVHD (grade II-IV), chronic GVHD and overall survival (OS). Other endpoints studied include hematopoietic recovery and disease-free survival (DFS). Neutrophil recovery was defined as first of three consecutive days with absolute neutrophil count ≥ 0.5×10 9 /L and platelets, ≥ 20×10 9 /L, unsupported for 7 days.
Acute grade II-IV GVHD and chronic GVHD were graded using standard criteria 17, 18 .
Disease free survival (DFS) was defined as survival without graft failure, a second transplantation or death. For analyses of OS, failure was defined as death from any cause;
surviving patients were censored at the date of last contact.
Statistical Analyses
Univariate probabilities of OS and DFS were calculated by the Kaplan-Meier estimator; the log-rank test was used for univariate comparisons. Probabilities of hematopoietic recovery and GVHD were calculated by using the cumulative incidence 
RESULTS

Patients
The demographic data are summarized in Table 1 . The median age at BMT was 7 years and the median follow-up among survivors was 6 years. The transplantation regimens for conditioning and GVHD prophylaxis were fairly uniform. All patients received busulfan and cyclophosphamide for transplant conditioning; busulfan (16 mg/kg) with cyclophosphamide (200 mg/kg) was the most frequent combination used. Almost all patients
For personal use only. on October 15, 2017. by guest www.bloodjournal.org From (98%) received cyclosporine-containing GVHD prophylaxis. There were significant transfusion exposures before BMT, in 85% of patients, more than 20 RBC units were administered and 62% of patients were transfused more than 50 RBC units before transplantation. Iron chelation therapy was deemed inadequate in 94% of the transplant recipients; inadequate chelation was defined as not initiating chelation therapy within 18 months of the first transfusion and administered subcutaneously for 8-10 hours per day at least 5 days/week. Inadequate iron chelation therapy in almost all patients and the presence of hepatomegaly and hepatic fibrosis in approximately 50% of patients imply most transplant recipients were in a high-risk category with respect to transplant-related morbidity and mortality. Of the 87% of recipients who had a liver biopsy performed before transplantation, 59% had histological evidence of portal fibrosis. Though serum bilirubin, was normal in 84% of patients, hepatic inflammation was common. The serum AST or ALT was greater than 2 times the upper limit of normal in more than 30% of patients. Only 9% of the patients had a documented pre-transplant history of viral hepatitis. Data about hepatic synthetic function was not collected.
Thus, among the 142 (79%) patients who were eligible for risk-group assignment, the assignment to risk categories was 2% to class I, 42% to class II and 36% to class III. It was not possible to assign a risk category in 20% of the study population. As there were so few patients who had class I features, the findings presented herein pertain to patients with class II and III risk-group features.
Hematopoietic recovery and graft failure
By day-30 after transplantation, the cumulative incidence of neutrophil recovery was For personal use only. on October 15, 2017. by guest www.bloodjournal.org From 90% (95% CI 85-94%) and platelet recovery, 51% (95% CI 43-58%). The cumulative incidence of platelet recovery by day-100 improved to 86% (95% CI 80-90%). We also examined for the effect of Pesaro risk group and of ATG on neutrophil recovery and did not observe significant differences. The day-30 cumulative incidence of neutrophil recovery for patients in Pesaro class II and class III were 92% (95% CI 85-97%) and 91% (95% CI 83-96%), respectively, p=0.44. Corresponding cumulative incidence of neutrophil recovery for patients who received ATG and did not receive ATG were 89% (95% CI 82-94%) and 91% (95% CI 84-94%), respectively, p=0.13. Seventeen patients (10%) had graft rejection that was fatal in 11 cases. Five of these 17 patients were assigned to Pesaro risk class II, 8 patients, risk class III and in the remaining 4 patients we could not assign a risk category.
Five patients with graft rejection received ATG.. Six of 9 patients with graft failure are alive and free of thalassemia after a successful second transplant. The source of hematopoietic cells for the second transplantation was bone marrow in 5 patients and 4 patients received mobilized peripheral blood stem cells.
Graft versus host disease
The day-100 probability of acute GVHD (grade II-IV) was 38% (95% CI 31-45%) and the 5-year probability of chronic GVHD was 13% (95% CI 9-18%). In multivariate analysis, the administration of >50 RBC transfusions before transplantation was associated with a lower risk of acute GVHD (RR 0.52, 95% CI 0.31-0.86, p=0.010). No risk factors were identified for the development of chronic GVHD. The use of ATG had no apparent association with the risk of GVHD in this analysis. Of those who received ATG before transplantation, 29 of 77 (38%) developed acute GVHD compared to 44 of 99 (44%) in patients who did not receive ATG. There was also no effect of ATG on the incidence of chronic GVHD, in which 10 of 77 (13%) who received ATG and 16 of 99 (16%) who did not receive ATG developed chronic GVHD.
Overall and disease-free survival Pesaro risk class had a significant association with survival in univariate analysis.
The 5-year overall survival was 91% (95% CI 83-96%) and 64% (95% CI 52-75%) in patients with risk class II and class III, respectively, p=0.0002 (Figure 3 particularly in iron chelation therapy, which have reduced the risks of morbidity and mortality in those who do not proceed to transplantation 2, 16, [19] [20] [21] . Our results confirm that HLA-matched sibling BMT for β -thalassemia major is a suitable therapeutic option to consider, as we also observed DFS rates that exceeded 90% in children with good-risk features (figure 1) 4, 9 . However, as noted in the initial Pesaro experience, children with highrisk features fared much worse, with an event-free survival rate that approached 50% 4, 22, 23 .
These observations underscore the importance of carefully selecting good-risk patients for transplantation, but also if treating high-risk patients, the importance of employing modifications to the transplantation regimen that might improve the safety of the procedue 6,7, 11, 24 .
We were able to identify two readily accessible prognostic indicators in a cohort of high-risk thalassemia recipients, namely liver size and patient age, which other groups also have identified 19, 20 . The observed effect of age and liver size were independent of each other though liver size is highly correlated with Pesaro risk group. By classifying this high-risk cohort by these criteria (i.e. age and liver size), it was possible to refine and broaden the class II and III Pesaro risk groupings into distinct patterns of survival and event-free survival that are represented in Figures 1 and 2 . The 5-year survival probabilities that ranged from 53% to 96%, are broader than the initial Pesaro experience. 4, 9, 20 While these criteria do not supplant the utility of a liver biopsy, which provides important information about liver histology and can also direct post-transplantation interventions to reduce iron overload, there may be situations where a liver biopsy and the ability to assess liver histology and iron concentration are not readily available. Using the risk features identified in the current analysis, it may be For personal use only. on October 15, 2017. by guest www.bloodjournal.org From possible to assign a conditioning therapy that is better suited to those who are most in need of such modifications and in clinical settings where assigning a Pesaro risk classification is not possible. 7, 12, 22 We speculate that for the diverse cohort in the current analysis, it may be appropriate to dispense with the Pesaro classification in high-risk patients, and rely upon this facile and novel risk assignment.
It appears that much of the toxicity of transplantation observed in this series might have been related to impaired hepatic function and a propensity for developing interstitial pneumonitis and VOD, particularly in the older, high-risk patients. Previously, a high rate of regimen-related toxicity and graft rejection was noted in class II and III patients after standard busulfan and cyclophosphamide preparation, particularly in young adult patients with thalassemia, for whom the transplant-related mortality was 35%. 25 An early study of busulfan pharmacokinetics as a predictor of clinical outcome in thalassemia major failed to identify a relationship between the busulfan level and toxicity, although this analysis included transplant regimens that differed in their cyclophosphamide dosing and in postgrafting immunosuppression. 26 Other studies in children with hematological malignancies have demonstrated the utility of busulfan pharmacokinetics in predicting the risk of toxicity and which have generally endorsed the adoption of targeted busulfan dosing to avoid this toxicity. [27] [28] [29] Moreover, a more recent clinical study defined the important contribution by cyclophosphamide and its metabolites to the toxicity of the busulfan and cyclophosphamide regimen, suggesting that the administration busulfan before cyclophosphamide alters cyclophosphamide pharmacokinetics and thus might also exacerbate the risk of VOD in patients with underlying hepatic injury. 30, 31 To mitigate these risks, investigative teams in Italy have reduced the dosing of cyclophosphamide in high-risk patients 7 . Alternatively, the replacement of cyclophosphamide with fludarabine might also mitigate the risk of significant transplant-related toxicity. 32 Intravenous busulfan in lieu of oral busulfan also appears to improve the safety profile of busulfan as does the practice of therapeutic drug monitoring. 11, [33] [34] [35] The observations made in this series thus highlight the importance of modifying the standard busulfan and cyclophosphamide regimen in very high-risk patients in order to avoid unacceptably high transplant-related mortality.
In other patient series, graft rejection after HLA-matched sibling BMT is generally accompanied by thalassemia recurrence and recovery of autologous hematopoietic function. 5, 36, 37 However, in this series graft failure, which occurred in nearly 10% of cases, was fatal in 11 cases and required rescue by second transplantation to restore normal hematopoiesis. The reasons for this are unclear. The use of ATG did not appear to be useful in reducing the risk of graft failure. In the future, it is possible that the development of alternative regimens that provide more intensive immune suppression before transplantation without myeloablation might reduce the elevated risk of graft failure we observed in high-risk patients with thalassemia. 24, 38 When defining the role of transplantation for ß-thalassemia major, which is a chronic, non-malignant condition, one must also consider the natural history of the disorder and the impact of improved supportive care measures on patient outcomes. In selected regions of the world, the outcomes are outstanding when there is ready access to expanded supportive care services, with very few individuals dying of thalassemia or of complications related to its treatment through the third and fourth decades of life. 12, 20, 21 In other areas of the world, For personal use only. on October 15, 2017. by guest www.bloodjournal.org From however, supportive care measures are often difficult to access, which as predicted, has had a negative impact on survival. 39, 40 We speculate that many of the transplant recipients included in this series lacked ready access to vital supportive care measures such as regular iron chelation therapy, and there may have been delays in proceeding to transplantation in cases where resources were limited. For these reasons, the results shown here reflect a variety of health care issues that have the potential to affect outcomes in children with ß- For personal use only. on October 15, 2017. by guest www.bloodjournal.org From
